Skip to main content
. 2019 Sep 13;8(10):1383–1394. doi: 10.1530/EC-19-0332

Figure 1.

Figure 1

Evolution of IGF-1 results (expressed relatively to the upper limit normal of the assay ULN) for each patient during combination therapy and at subsequent evaluations (ev) following the switch to Pasireotide-LAR. The broken line is set at the upper limit of ‘controlled’ IGF-1 levels (1.3 ULN).